Pre-pandemic, the FDA set a goal of increasing inspections of drug-manufacturing facilities located outside the US. Has the agency made progress? A look at what the numbers say.
Small molecules again dominated new drug approvals by the FDA in 2021, but which companies had approvals? Is innovation coming from the large or small companies?
The CDMO/CMO Report: Expansions in Parenteral Drug Mfg
Increased demand in biologic-based drug development and for COVID-19 vaccines/drugs is driving demand for parenteral drug manufacturing. Which CDMOs/CMOs are expanding?
Off the Charts: Pfizer Sets Industry Record for Revenues
Led by its COVID-19 vaccine, Pfizer reported record-breaking 2021 revenues, both on an industry and company level. What were its revenue gains, and how did its other products fare?
Industry Radar: Potential Blockbusters Launching in 2022
Which drugs projected to launch in 2022 are slated for blockbuster potential? A look at the 10 biggest potential product launches in 2022 and other high-valued drug candidates.
Pharma Pulse: Top-Selling Small Molecules & Biologics
How do small molecules and biologics rank among the projected top-selling products for 2022? Which products will be the greatest new sales generators? A look at the projections and products.
CDMOs & Pharma: How are Supply Practices Changing?
What are the most significant issues shaping the pharma customer–supplier relationship in 2022? Industry leaders weigh in on changing supply practices and project management in a post-pandemic world.
New Drug Approvals in 2021: The Numbers and Trends
FDA approval of new molecular entities is a measure of product innovation in the bio/pharma industry. How did the industry fare in 2021? A look at the numbers and key trends.
Big Pharma and Sustainability: Tracking Companies’ Goals
In 2022, both the EU and the US will continue policy moves to evaluate vulnerabilities in bio/pharma supply chains and recommend solutions to address those vulnerabilities.
